The Lancet recently published a Series with updated information and guidance on malaria in pregnancy. Despite advances in knowledge, prevention and treatment, malaria remains one of the most preventable causes of poor birth outcomes in many parts of the world—and continues to play a large role in global maternal deaths. Resistance to sulfadoxine–pyrimethamine, the intermittent preventive treatment in pregnancy (IPTp) drug combination, as well as inadequate coverage of IPTp and insecticide-treated nets pose key challenges to addressing malaria in pregnancy worldwide.
The Series covers the current burden, pathology, costs, prevention and treatment of both uncomplicated and severe malaria during pregnancy. As the Series states,
This new Series puts the spotlight back on malaria in pregnancy where much can still be achieved with what is currently understood. However, renewed dialogue and collaboration between researchers, policy makers, and funders could reap enormous benefits if the roadmap as laid out is followed.
Access the Series below: